Integrating single-cell and spatial analysis reveals MUC1-mediated cellular crosstalk in mucinous colorectal adenocarcinoma

Abstract

Tumour microenvironment profiling of MCA is developed

MUC1⁺ tumour cells interplay with FGF7⁺/THBS1⁺ myofibroblasts to promote MCA development.

MS4A4A⁺ macrophages exhibit M2 phenotype in MCA.

ZEB1⁺ endotheliocytes engage in EndMT process in MCA.

Keywords

mucinous colorectal adenocarcinoma / scRNA-seq / spatial transcriptomics / tumour microenvironment

References

[1] HugenN, BrownG, Glynne-JonesR, et al. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361-369.

[2] LuoC, CenS, DingG, et al. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13.

[3] VerhulstJ, Ferdinande L, DemetterP, et al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012;65(5):381-388.

[4] KoëterT, StijnsRCH, KoeverdenS, et al. Poor response at restaging MRI and high incomplete resection rates of locally advanced mucinous rectal cancer after chemoradiation therapy. Colorectal Disease. 2021;23(9):2341-2347.

[5] McCawleyN, ClancyC, O'NeillBD, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis Colon Rectum. 2016;59(12):1200-1208.

[6] KimJH, ParkHE, ChoNY, et al. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115(4):490-496.

[7] NitscheU, Zimmermann A, SpathC, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258(5):775-782. discussion 82-3.

[8] YanX, ChengY, ZhangX, et al. NICD3 regulates the expression of MUC5AC and MUC2 by recruiting SMARCA4 and is involved in the differentiation of mucinous colorectal adenocarcinoma. Mol Oncol. 2022;16(19):3509-3532.

[9] LuoCCS, DingG, WuW. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13.

[10] PerezRO, Bresciani BH, BrescianiC, et al. Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. Int J Colorectal Dis. 2008;23(8):757-765.

[11] KufeDW. Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther. 2014;7(1):81-84.

[12] BaslanT, HicksJ. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017;17(9):557-569.

[13] SuvaML, TiroshI. Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell. 2019;75(1):7-12.

[14] EngblomC, Pfirschke C, PittetMJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447-462.

[15] ZengQ, MousaM, NadukkandyAS, et al. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat Rev Cancer. 2023;23(8):544-564.

[16] FangJ, LuY, ZhengJ, et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023;14(9):586.

[17] De WeverO, Demetter P, MareelM, et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123(10):2229-2238.

[18] WuSY, FuT, JiangYZ, et al. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.

[19] GlabmanRA, ChoykePL, SatoN. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel). 2022;14(16).

[20] ValesS, BacolaG, BiraudM, et al. Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis. EBioMedicine. 2019;49:172-188.

[21] BeatsonR, Tajadura-Ortega V, AchkovaD, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17(11):1273-1281.

[22] ZhengX, WuY, BiJ, et al. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022;19(2):192-209.

[23] HenkeE, Nandigama R, ErgunS. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2019;6:160.

[24] LichtermanJN, ReddySM. Mast cells: a new frontier for cancer immunotherapy. Cells. 2021;10(6).

[25] LuP, WeaverVM, WerbZ. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406.

[26] ThieryJP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-454.

[27] NersisyanS, Novosad V, EngibaryanN, et al. ECM-receptor regulatory network and its prognostic role in colorectal cancer. Front Genet. 2021;12:782699.

[28] LeitingerB. Pulling the strings of tumor collagen. Nat Cancer. 2022;3(1):9-10.

[29] XieN, XiaoC, ShuQ, et al. Cell response to mechanical microenvironment cues via Rho signaling: from mechanobiology to mechanomedicine. Acta Biomaterialia. 2023;159:1-20.

[30] LiuY, ZhangJ, LiY, et al. Matrix stiffness-dependent microglia activation in response to inflammatory cues: in situ investigation by scanning electrochemical microscopy. Chem Sci. 2024;15(1):171-184.

[31] XuF, GuoH, ZustiakSP, et al. Targeting the physical microenvironment of tumors for drug and immunotherapy. Adv Drug Deliv Rev. 2023;196.

[32] PrestaM, Chiodelli P, GiacominiA, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171-187.

[33] NakamuraK, SmythMJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1-12.

[34] van Vlerken-YslaL, Tyurina YY, KaganVE, et al. Functional states of myeloid cells in cancer. Cancer cell. 2023;41(3):490-504.

[35] LiC, XuX, WeiS, et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9(1).

[36] LiY, ShenZ, ChaiZ, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. 2023;72(12):2307-2320.

[37] ClereN, Renault S, CorreI. Endothelial-to-mesenchymal transition in cancer. Front Cell Dev Biol. 2020;8:747.

[38] SteeleCD, AbbasiA, IslamSMA, et al. Signatures of copy number alterations in human cancer. Nature. 2022;606(7916):984-991.

[39] TaylorAM, ShihJ, HaG, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676-689. e3.

[40] DavoliT, UnoH, WootenEC, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322).

[41] WangT, JinH, HuJ, et al. COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling. J Exp Clin Cancer Res. 2020;39(1):148.

[42] ZhaoX, ZhangT, YanY, et al. Notch signaling regulates vessel structure and function via Hspg2. Gene. 2022;826.

[43] OltedalS, Kørner H, AasprongOG, et al. The prognostic relevance of sentinel lymph node metastases assessed by PHGR1 mRNA quantification in stage I to III colon cancer. Transl Oncol. 2018;11(2):436-443.

[44] CuiHY, WangSJ, SongF, et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct Target Ther. 2021;6(1).

[45] ChenB, XiaZ, DengYN, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 2019;9(1):180212.

[46] CortezMA, Anfossi S, RamapriyanR, et al. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244-253.

[47] PolytarchouC, HommesDW, PalumboT, et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology. 2015;149(4):981-992. e11.

[48] YeMF, LinD, LiWJ, et al. MiR-26a-5p serves as an oncogenic MicroRNA in non-small cell lung cancer by targeting FAF1. Cancer Manag Res. 2020;12:7131-7142.

[49] ShenJ, LiM. MicroRNA-744 inhibits cellular proliferation and invasion of colorectal cancer by directly targeting oncogene Notch1. Oncol Res. 2018;26(9):1401-1409.

[50] Cruz-GilS, Sanchez-Martinez R, Gomez de CedronM, et al. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. J Lipid Res. 2018;59(1):14-24.

[51] ZhangN, ZhangH, LiuY, et al. SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ. 2019;26(5):843-859.

[52] NegriFV, Wotherspoon A, CunninghamD, et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16(8):1305-1310.

[53] CatalanoV, Loupakis F, GrazianoF, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009;100(6):881-887.

[54] SunW, SunY, ZhuM, et al. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol Rep. 2014;31(3):1466-1472.

[55] SunG, WuL, SunG, et al. WNT5a in colorectal cancer: research progress and challenges. Cancer Manag Res. 2021;13:2483-2498.

[56] KimJH, SeoMK, LeeJA, et al. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. J Immunother Cancer. 2021;9(12).

[57] LiP, HuangT, ZouQ, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol. 2019;202(10):3065-3075.

[58] LiuX, XuD, LiuZ, et al. THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition. Clin Transl Oncol. 2020;22(10):1730-1740.

[59] NathS, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332-342.

[60] GaoT, CenQ, LeiH. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020;132:110888.

[61] KufeDW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012;32(9):1073-1081.

[62] DengJ, WangL, ChenH, et al. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev. 2013;32(3-4):535-551.

[63] HuangT, WangL, LiuD, et al. FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. Int J Oncol. 2017;50(5):1501-1512.

[64] IsidroRA, Appleyard CB. Colonic macrophage polarization in homeostasis, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol. 2016;311(1):G59-G73.

[65] XiaQ, JiaJ, HuC, et al. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene. 2022;41(6):865-877.

[66] QiJ, SunH, ZhangY, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742.

[67] TaniaM, KhanMA, FuJ. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014;35(8):7335-7342.

[68] ChoiSH, KimAR, NamJK, et al. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6(+) cancer cell and macrophage polarization. Nat Commun. 2018;9(1):5108.

[69] ChoiKJ, NamJK, KimJH, et al. Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage. Exp Mol Med. 2020;52(5):781-792.

[70] StuartT, ButlerA, HoffmanP, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888-1902. e21.

[71] SquairJW, Gautier M, KatheC, et al. Confronting false discoveries in single-cell differential expression. Nat Commun. 2021;12(1):5692.

[72] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

[73] WuT, HuE, XuS, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.

[74] Gene Ontology C. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res 2021;49(D1):D325-D334.

[75] KanehisaM, Furumichi M, TanabeM, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353-D361.

[76] LiberzonA, BirgerC, ThorvaldsdottirH, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-425.

[77] Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.

[78] JinS, Guerrero-Juarez CF, ZhangL, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088.

[79] HaoY, HaoS, Andersen-NissenE, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587. e29.

[80] Cole TrapnellDC, Grimsby J, PokharelP, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32(4):381-386.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.